Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GSK Analyst Ratings
Hold
3 Buy
7 Hold
3 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GSK Stock 12 Month Forecast
Average Price Target
1,623.25p
▼(-1.02% Downside)
| Highest Price Target2,170p | Average Price Target1,623p | Lowest Price Target1,345p |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
1,400p
Sell
-14.63%
Downside
Reiterated
10/27/25
UBS
1,450p→2,000p
Buy
21.95%
Upside
Upgraded
10/26/25
Barclays
1,450p
Hold
-11.59%
Downside
Reiterated
10/24/25
Morgan Stanley
1,345p
Sell
-17.99%
Downside
Reiterated
10/24/25
Sell Rating for GlaxoSmithKline Due to Limited Growth Prospects for Blenrep Amid Competitive Challenges and Regulatory HurdlesWe forecast peak Blenrep sales of ~£600m in the R/R multiple myeloma setting and ascribe limited to no sales for earlier line use (DREAMM-10 trial). the front line (DREAMM-10) setting continues, though trial design uncertainty remains (data expected in 2031). The ongoing front-line trial (DREAMM-10) could face similar issues to later line trials given: (1) potential under-dosing, utilising the 1.9mg/kg dose every 8 weeks, then 12 weeks. While 1.9mg /kg was used as the maintenance dose in the DREAMM-8 trial, it was noted in the ODAC that there was an efficacy loss, without a noticeable safety gain. Importantly, the interval between doses has been extended to 8-12 weeks (vs 4 weeks in DREAMM-8), which again, could be detrimental to efficacy. (2) Uncertainty around sufficient US enrolment.
TR | OpenAI - 4o
1,610p→1,884p
Buy
14.88%
Upside
Reiterated
10/23/25
AI Generated ArticleAI Generated Article
Bank of America Securities
1,434p
Sell
-12.56%
Downside
Reiterated
10/23/25
Kepler Capital
1,500p
Hold
-8.54%
Downside
Reiterated
10/22/25
Goldman Sachs
1,550p→1,580p
Hold
-3.66%
Downside
Reiterated
09/30/25
Berenberg Bank
1,600p
Hold
-2.44%
Downside
Reiterated
09/17/25
Bernstein
2,290p→2,170p
Buy
32.32%
Upside
Reiterated
08/06/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
1,400p
Sell
-14.63%
Downside
Reiterated
10/27/25
UBS
1,450p→2,000p
Buy
21.95%
Upside
Upgraded
10/26/25
Barclays
1,450p
Hold
-11.59%
Downside
Reiterated
10/24/25
Morgan Stanley
1,345p
Sell
-17.99%
Downside
Reiterated
10/24/25
Sell Rating for GlaxoSmithKline Due to Limited Growth Prospects for Blenrep Amid Competitive Challenges and Regulatory HurdlesWe forecast peak Blenrep sales of ~£600m in the R/R multiple myeloma setting and ascribe limited to no sales for earlier line use (DREAMM-10 trial). the front line (DREAMM-10) setting continues, though trial design uncertainty remains (data expected in 2031). The ongoing front-line trial (DREAMM-10) could face similar issues to later line trials given: (1) potential under-dosing, utilising the 1.9mg/kg dose every 8 weeks, then 12 weeks. While 1.9mg /kg was used as the maintenance dose in the DREAMM-8 trial, it was noted in the ODAC that there was an efficacy loss, without a noticeable safety gain. Importantly, the interval between doses has been extended to 8-12 weeks (vs 4 weeks in DREAMM-8), which again, could be detrimental to efficacy. (2) Uncertainty around sufficient US enrolment.
TR | OpenAI - 4o
1,610p→1,884p
Buy
14.88%
Upside
Reiterated
10/23/25
AI Generated ArticleAI Generated Article
Bank of America Securities
1,434p
Sell
-12.56%
Downside
Reiterated
10/23/25
Kepler Capital
1,500p
Hold
-8.54%
Downside
Reiterated
10/22/25
Goldman Sachs
1,550p→1,580p
Hold
-3.66%
Downside
Reiterated
09/30/25
Berenberg Bank
1,600p
Hold
-2.44%
Downside
Reiterated
09/17/25
Bernstein
2,290p→2,170p
Buy
32.32%
Upside
Reiterated
08/06/25
Best Analysts Covering GlaxoSmithKline
1 Month
xxx
Success Rate
3/6 ratings generated profit
Average Return
-1.42%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -1.42% per trade.
3 Months
xxx
Success Rate
8/14 ratings generated profit
Average Return
+0.14%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.14% per trade.
1 Year
Success Rate
15/22 ratings generated profit
Average Return
+5.99%
upgraded a buy rating 3 days ago
Copying Michael Leuchten's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of +5.99% per trade.
2 Years
xxx
Success Rate
9/14 ratings generated profit
Average Return
+6.24%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +6.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GSK Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
2
2
0
0
0
Buy
38
41
39
23
10
Hold
30
49
45
40
11
Sell
3
4
3
5
2
Strong Sell
5
6
6
6
4
total
78
102
93
74
27
Each month's total comprises the sum of three months' worth of ratings.
GSK Financial Forecast
GSK Stock Forecast FAQ
What is GB:GSK’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 1,623.25.
What is GB:GSK’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for GB:GSK, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GlaxoSmithKline a Buy, Sell or Hold?
GlaxoSmithKline has a consensus rating of Hold, which is based on 3 buy ratings, 7 hold ratings and 3 sell ratings.
What is GlaxoSmithKline’s share price target?
The average share price target for GlaxoSmithKline is 1,623.25. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,170.00p ,and the lowest forecast is 1,345.00p. The average share price target represents -1.02% Decrease from the current price of 1,640p.
The highest analyst share price target is 2,170.00p ,and the lowest forecast is 1,345.00p. The average share price target represents -1.02% Decrease from the current price of 1,640p.
What do analysts say about GlaxoSmithKline?
GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of GlaxoSmithKline?
To buy shares of GB:GSK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.